Neotropix began operations in 2005 to develop and commercialize
naturally derived, systemically deliverable oncolytic viruses for the
treatment of solid tumors. By applying its proprietary screening process,
called ViruScreen, to previously untapped viral resources, Neotropix
has uncovered at least 19 entirely novel oncolytic candidates.
|
 |